Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sucrose + povidone iodine
- Development stage
- Unknown
- Lead developer
- Teika Pharmaceutical
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Sucrose + povidone iodine (also known as sucrose/povidone-iodine or SPI, marketed under the brand name U-PASTA) is an approved topical combination therapy developed by Kowa for the treatment of pressure ulcers (bedsores) and skin ulcers (such as burn ulcers and diabetic ulcers). The formulation typically consists of 70% purified sucrose (white sugar) and 3% povidone iodine. Sucrose acts as an osmotic agent that reduces localized edema, absorbs wound exudate, and stimulates granulation tissue formation and epidermal regeneration. Povidone iodine serves as a broad-spectrum antiseptic that slowly releases free iodine to exert bactericidal activity against a wide range of pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), thereby preventing and treating wound infections. The ointment is applied topically to the cleaned wound surface.
- Brand names
- Isodine Sugar PastaNegmin SugarNeoyojin Sugar PastaPobi Sugar PastaPobidrin PastaSucroad PastaU-PASTAU-PASTA KOWA
- Other names
- SPIpurified sucrose + povidone iodinepurified sucrose/povidone-iodinesucrose povidone-iodinesucrose/povidone-iodinesugar + povidone iodinesugar/povidone-iodine
Beyond the preview
Go deeper on sucrose + povidone iodine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sucrose + povidone iodine.